| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sporos Bioventures LLC | 9% | $19,544,812 | 837,636 | Sporos Bioventures LLC | 15 Apr 2025 | |||
| Solas Tvardi Sidecar LLC | 8.1% | $4,050,047 | 761,287 | Solas Tvardi Sidecar LLC | 15 Apr 2025 | |||
| Tweardy David John | 7% | $3,470,757 | 652,398 | David J. Tweardy | 15 Apr 2025 | |||
| DePinho Ronald A | 6.7% | -20% | $24,413,770 | -$6,035,311 | 626,190 | -20% | Ronald A. DePinho | 30 Sep 2025 |
| Tweardy Samuel David | 3.4% | -67% | $7,365,343 | -$14,730,686 | 315,658 | -67% | Samuel D. Tweardy | 07 Jul 2025 |
As of 30 Sep 2025, 8 institutional investors reported holding 22,165 shares of TVARDI THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (CARA). This represents 0.24% of the company’s total 9,346,119 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 127 | $546 | +$546 | $4.30 | 1 |
| 2025 Q3 | 22,165 | $862,745 | +$8,201 | $39.00 | 8 |
| 2025 Q2 | 21,929 | $511,606 | -$2,705,206 | $23.33 | 7 |
| 2025 Q1 | 633,363 | $3,211,465 | -$2,599,722 | $5.07 | 33 |
| 2024 Q4 | 1,075,203 | $6,580,102 | +$6,496,611 | $6.12 | 39 |
| 2024 Q3 | 250 | $77 | +$77 | $0.31 | 1 |